A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

NCT03273153 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

446

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated due to benefit/risk analysis.

Conditions

Advanced BRAFV600 Wild-type Melanoma

Interventions

DRUG: Cobimetinib
DRUG: Atezolizumab
DRUG: Pembrolizumab

Sponsor

Hoffmann-La Roche